Tuesday, ANI Pharmaceuticals, Inc. (ANIP) announced that it received approval from the U.S. Food and Drug Administration for the Abbreviated New Drug Application or ANDA and launched Naproxen Delayed-Release Tablets, USP.
The company also stated that its Naproxen Delayed-Release Tablets, a nonsteroidal anti-inflammatory drug used to relieve mild to moderate pain and inflammation, is the generic version of the reference-listed drug, EC-Naprosyn.
According to IQVIA data from April 2024, U.S. annual sales for Naproxen Delayed-Release Tablets amount to around $36.7 million.
ANIP's stock on the Nasdaq closed at $63.44, down 0.38% on July 1.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.